Who Should—and Can—Get Lecanemab, the New Alzheimer Disease Drug? | Dementia and Cognitive Impairment | JAMA

This Medical News story examines the complexity of determining who to treat with lecanemab, the new Alzheimer disease drug.

Related Keywords

United Kingdom ,Ohio ,United States ,New York ,Kansas ,Minnesota ,George Perry ,Donna Wilcock ,Eli Lilly ,Russell Swerdlow ,James Burke ,Sam Grandy ,Madhav Thambisetty ,Alzeca Bioscience ,Robert Howard ,Libby Holman ,Ivan Cheung ,Xavier Becerra ,David Knopman ,Allison Parks ,Bioenergetically Active Esters For Health ,Recuerdo Pharmaceuticals ,Cure Alzheimer Fund ,Alzheimer Network For Treatment ,Us Department Of Health ,York Stem Cell Foundation ,University Of Texas At San Antonio ,Translational Neuroscience Section Laboratory Of Behavioral ,Centers For Medicare Medicaid Services ,National Institutes Of Health ,Brightfocus Foundation ,Mcknight Brain Research Foundation ,Indiana University ,Indiana University School Of Medicine ,National Institute On Aging ,Pfizer ,Drug Administration ,Lilly Pharmaceuticals ,University Of Kansas Alzheimer Disease Research Center ,Astrazeneca ,Nestle Health Science ,Journal Of The Alzheimer Association ,University College London ,Human Services ,Alzheimer Network Treatment Unit ,University Of Southern California ,Alzheimer Association ,Johnson ,Kansas Alzheimer Disease Research ,San Antonio ,Might Benefit ,Who Might ,New England Journal ,Indiana University School ,Ohio State ,Medicaid Services ,Monoclonal Antibodies Directed Against Amyloid ,Disease Registry ,Alzheimer Network ,Chiquita Brooks Lasure ,National Institutes ,National Institute ,Translational Neuroscience Section Laboratory ,Mount Sinai ,Mayo Clinic Study ,Interest Disclosures ,Cognito Therapeutics ,Third Bridge ,Vigil Neurosciences ,Cure Alzheimer ,New York Stem Cell Foundation ,Southern California ,Samus Therapeutics ,Active Esters ,Nestle Health ,Central Nervous System ,Psychopharmacologic Drugs ,